Avitar
OTCMKTS:AVTIAvitar, Inc. is a holding company which through its subsidiaries designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine such as crack; marijuana; and methamphetamines, including meth and ecstasy. The company also provides foam disposable products including medical-grade hydrophilic polyurethane foam disposables such as wound dressings comprising Hydrasorb, a wound dressing product for exudating wounds; and various custom foam products comprising a sinus dressing and a device used by astronauts for relieving ear pressure while in a pressurized space suit. In addition, it develops specialty wound dressings for the cardiac catheter lab market, as well as the Illizarov Dressing used for dressing external bone fixators in orthopedic procedures. The company markets its products and services to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations through direct sales force and strategic partners, as well as through a network of distributors. Avitar, Inc. was founded in 1986 and is based in Canton, Massachusetts with Additional office in Calgary, Canada.
Ortho Regenerative Technologies
OTCMKTS:ORTIFOrtho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.
PC Group
OTCMKTS:PCGRPC Group, Inc., through its subsidiaries, offers personal care products for the private label retail, medical, and therapeutic markets primarily in the United States, Canada, and Europe. Its personal care products include soaps, cleansers, toners, moisturizers, exfoliants, and facial masks, as well as over-the-counter drug products, such as acne soaps; and gel-based products, including gloves and sock products that are used for cosmetic and scar management purposes. The company's gel-based orthopedic products include digitcare products, diabetes management products, products that protect the hands and wrists, gel sheeting products for various applications, and pressure, friction, and shear force absorption products, as well as products for the treatment of common orthopedic and footcare conditions; and gel-based prosthetic products for the treatment of common orthopedic and footcare conditions. PC Group sells its personal care products through account representatives to health and beauty companies, specialty retailers, cosmetics companies, direct marketing companies, amenities companies, health clubs and spas, and catalog companies; and medical products through national and regional account managers, field sales representatives, and inside sales representatives, as well as through medical distributors. The company was formerly known as Langer, Inc. and changed its name to PC Group, Inc. in July 2009 as a result of business focus shift to personal care products business. PC Group, Inc. was founded in 1971 and is headquartered in New York, New York.
Pathfinder Cell Therapy
OTCMKTS:PFNDPathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.